# C_2021099EN.01001901.xml

| 23.3.2021 | EN | Official Journal of the European Union | C 99/19 |
| --- | --- | --- | --- |

23.3.2021

EN

Official Journal of the European Union

C 99/19

---

Prior notification of a concentration

(Case M.10133 — Astorg/Nordic Capital/Novo/Bioclinica)

(Text with EEA relevance)

(2021/C 99/11)

1.

This notification concerns the following undertakings:

| — | Astorg Asset Management S.à r.l. (‘Astorg’, Luxembourg) |
| --- | --- |

—

Astorg Asset Management S.à r.l. (‘Astorg’, Luxembourg)

| — | Nordic Capital IX Limited (‘Nordic Capital’, Jersey) |
| --- | --- |

—

Nordic Capital IX Limited (‘Nordic Capital’, Jersey)

| — | Novo Holdings A/S (‘Novo’, Denmark) |
| --- | --- |

—

Novo Holdings A/S (‘Novo’, Denmark)

| — | Bioclinica Holding I LP (‘Bioclinica’, USA) |
| --- | --- |

—

Bioclinica Holding I LP (‘Bioclinica’, USA)

Astorg, Nordic Capital and Novo acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Bioclinica through eResearch Technology, Inc (‘ERT’, USA).

The concentration is accomplished by way of purchase of shares.

2.

| — | for Astorg: a global private equity firm, |
| --- | --- |

—

for Astorg: a global private equity firm,

| — | for Nordic Capital: a private equity firm focused on healthcare, technology & payments, financial services, and industrial & business services, |
| --- | --- |

—

for Nordic Capital: a private equity firm focused on healthcare, technology & payments, financial services, and industrial & business services,

| — | for Novo: a holding company responsible for the management of the assets of the Novo Nordisk Foundation through investments in the life sciences and related areas and through minority investments of a financial and venture capital nature, |
| --- | --- |

—

for Novo: a holding company responsible for the management of the assets of the Novo Nordisk Foundation through investments in the life sciences and related areas and through minority investments of a financial and venture capital nature,

| — | Astorg, Nordic Capital, and Novo jointly control ERT, a provider of software-enabled clinical research solutions, |
| --- | --- |

—

Astorg, Nordic Capital, and Novo jointly control ERT, a provider of software-enabled clinical research solutions,

| — | for Bioclinica: a provider of software-enabled clinical research solutions, including medical imaging and cardiac safety services, clinical adjudication, randomization and trial supply management and optimization solutions, electronic and eSource data capture, clinical trial management software, and drug safety solutions. |
| --- | --- |

—

for Bioclinica: a provider of software-enabled clinical research solutions, including medical imaging and cardiac safety services, clinical adjudication, randomization and trial supply management and optimization solutions, electronic and eSource data capture, clinical trial management software, and drug safety solutions.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10133 — Astorg/Nordic Capital/Novo/Bioclinica

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---